For example, since lenvatinib strongly inhibits VEGF and fibroblast growth factor receptor (FGFR), VEGFR and FGFR dual inhibition would contribute to increasing antitumor immunity by reduction of the tumor-associated macrophages and anti-angiogenesis39. The gene discussed is KDR; the disease is neoplasm.